Welcome to our dedicated page for PolyPid Ltd. Ordinary Shares news (Ticker: PYPD), a resource for investors and traders seeking the latest updates and insights on PolyPid Ltd. Ordinary Shares stock.
PolyPid Ltd. (Nasdaq: PYPD) is a cutting-edge biopharmaceutical company focused on enhancing surgical outcomes through its innovative drug delivery technology, PLEX™ (Polymer-Lipid Encapsulation matriX). This proprietary technology allows for the precise, prolonged release of drugs directly at the target site, optimizing therapeutic performance and clinical outcomes. PolyPid specializes in the development and manufacturing of products that address unmet medical needs, particularly in the prevention of surgical site infections (SSIs) and treatment of solid tumors.
The company's lead product candidate, D-PLEX100, is designed to provide localized, controlled anti-bacterial activity at surgical sites to prevent SSIs. It is currently undergoing a Phase 3 clinical trial, known as SHIELD II, aimed at preventing infections in patients undergoing open abdominal colorectal surgery. D-PLEX100 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential to address significant medical needs.
PolyPid's product pipeline also includes OncoPLEX, intended for the treatment of solid tumors, beginning with glioblastoma. This product is currently in preclinical stages, showing promising potential in oncology. Additionally, the company's proprietary technology, PLEX™, can encapsulate various drugs, enabling targeted and localized delivery over extended periods, ranging from several days to months.
In terms of recent achievements, PolyPid has successfully enrolled and randomized over 200 patients in its SHIELD II trial, with top-line results expected in the second half of 2024. Moreover, the company recently closed a $16 million private placement financing, which will support ongoing clinical development efforts and extend its cash runway beyond the anticipated interim analysis of the SHIELD II trial.
For more detailed information, visit PolyPid's official website or follow the company on Twitter and LinkedIn.
PolyPid Ltd. (Nasdaq: PYPD) announced that it will disclose its Q1 2023 financial results and operational highlights on May 10, 2023, before U.S. market opening. This marks a critical period as the company aims to enhance surgical outcomes with its innovative technology. A conference call is scheduled for 8:30 AM ET that day to discuss the results and future business updates.
PolyPid's lead product candidate, D-PLEX100, is undergoing Phase 3 trials targeting surgical site infections, while the company is also exploring OncoPLEX for treating solid tumors, starting with glioblastoma. Investors and analysts are eagerly awaiting insights that could influence stock performance.
PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company focused on enhancing surgical outcomes, announced its participation in several upcoming investor conferences. The events include:
- Aegis Capital Corp. Virtual Conference: May 3, 2023, at 10:30 AM ET
- Sidoti & Company Micro-Cap Virtual Conference: May 11, 2023, at 9:15 AM ET
- JMP Securities Life Sciences Conference: May 15, 2023, at 2:30 PM ET
During these conferences, PolyPid's management will engage in one-on-one investor meetings. The company aims to provide insights into its lead product candidate, D-PLEX100, currently in Phase 3 trials for preventing surgical site infections. Furthermore, PolyPid is exploring OncoPLEX for solid tumor treatments, including glioblastoma.
PolyPid Ltd. (Nasdaq: PYPD) has received a notification from Nasdaq regarding its non-compliance with the minimum stockholders' equity requirement of $10 million, as its equity stood at only $5.83 million as of December 31, 2022. The company has 45 days to submit a compliance plan, potentially extending the deadline for compliance verification by 180 days. The notification does not affect its current listing status, as shares will continue to trade on Nasdaq during this period. Following a recent offering that raised approximately $11.4 million, PolyPid is optimistic about regaining compliance. The company is focused on improving surgical outcomes through its proprietary PLEX technology and has a lead product candidate in Phase 3 trials aimed at preventing surgical site infections.
FAQ
What is the current stock price of PolyPid Ltd. Ordinary Shares (PYPD)?
What is the market cap of PolyPid Ltd. Ordinary Shares (PYPD)?
What is PolyPid Ltd. known for?
What is D-PLEX100?
What clinical trials is PolyPid currently conducting?
What is the PLEX™ technology?
What are PolyPid’s recent financial achievements?
What recognition has D-PLEX100 received?
What other products are in PolyPid’s pipeline?
Where can I find more information about PolyPid?
What is the target market for PolyPid's products?
Who are the key investors in PolyPid?
